Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leuprolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.84 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.87 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
| ▸ | APLNR | P35414 | 5/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leuprolide SCHEMBL570851 | 1.00 | ABCC2 (0.87) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL177978 | 1.00 | ABCC2 (0.87) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3174 | 1.00 | ABCC2 (0.87) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Deslorelin SCHEMBL1649660 | 0.99 | GNRHR (0.86) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL10061885 | 0.99 | GNRHR (0.86) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL21540132 | 0.99 | GNRHR (0.86) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL4585 | 0.99 | GNRHR (0.86) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL7751433 | 0.99 | GNRHR (0.86) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL4414320 | 0.98 | ABCC2 (0.84) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3915060 | 0.98 | GNRHR (0.86) | ABCC2GNRHRPTGS1APLNRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058271-A1 | Methods for screening, studying, and treating dissorders with a component of mercurial toxicity | GEIER, DAVID A. | 2006-03-16 | — | — | US | claimed |
| US-20230044690-A1 | PROGESTERONE FORMULATION TO TRIGGER OVULATION AND PROVIDE LUTEAL PHASE SUPPORT | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2021133430-A1 | PROGESTERONE FORMULATION TO TRIGGER OVULATION AND PROVIDE LUTEAL PHASE SUPPORT | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-2358392-B1 | ANTIBODY FORMULATION | MEDIMMUNE LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2724728-B1 | COMPLEXES OF IL-15 AND IL-15R ALPHA AND USES THEREOF | US HEALTH (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-2737907-A2 | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease | MedImmune, LLC (US) | 2014-06-04 | — | — | EP | disclosed |
| EP-2724727-A1 | Complexes of IL-15 and IL-15R alpha and uses thereof | The United States of America, as Represented by The Secretary, Department of Health and Human Services (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2724728-A1 | Complexes of IL-15 and IL-15R alpha and uses thereof | The United States of America, as Represented by The Secretary, Department of Health and Human Services (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2173378-B1 | COMPLEXES OF IL-15 AND IL-15RALPHA AND USES THEREOF | ADMUNE THERAPEUTICS LLC (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2703011-A2 | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease | MedImmune, LLC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20060100197-A1 | Fused-ring pyridine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060058271-A1 | Methods for screening, studying, and treating dissorders with a component of mercurial toxicity | GEIER, DAVID A. | 2006-03-16 | — | — | US | disclosed |
| EP-1593680-A1 | FUSED-RING PYRIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| CN-1505537-A | Disease prevention by reactivation of the thymus | Ī��ʲ��ѧ | 2004-06-16 | — | — | CN | disclosed |
| US-6197337-B1 | DECREASING ATHEROSCLEROSIS IN HUMANS AND ANIMALS | WEISMAN KENNETH (US) | 2001-03-06 | — | — | US | disclosed |
| US-5985877-A | Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer | CEPHALON, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0094157-B1 | PHARMACEUTICAL COMPOSITION AND ITS USE | Takeda Chemical Industries, Ltd. (JP) | 1987-07-29 | — | — | EP | disclosed |
| US-4670419-A | POLYPEPTIDE AND CYCLODEXTRIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-06-02 | — | — | US | disclosed |
| US-4659696-A | MIXTURE OF POLYPEPTIDE AND CYCLODEXTRIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-04-21 | — | — | US | disclosed |
| EP-0094157-A1 | Pharmaceutical composition and its use | Takeda Chemical Industries, Ltd. (JP) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100197-A1 | Fused-ring pyridine derivative, process for producing the same, and use | CCR5, CXCR4, CCR4 | GNRHR 1443/4885ABCC2 1060/4885PTGS1 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.